Ikena Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IKNA research report →
Range $1.33 – $1.33
Price Chart
About the company
Ikena Oncology, Inc. is a biopharmaceutical company specializing in precision oncology. Its primary objective is to create therapeutic agents specifically formulated for patient populations identified through biomarkers, thereby addressing significant unmet medical needs.
- CEO
- Mark Manfredi
- IPO
- 2021
- Employees
- 10
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on IKNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $718.82M
- P/E
- -0.82
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.48
- EV/EBITDA
- 0.84
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.99%
- ROIC
- -39.76%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-48,451,000
- Net Income
- $-52,395,000-6.4%
- EPS
- $0.00+100.0%
- OCF Growth
- -4.0%
- FCF Growth
- -4.0%
- 52W High
- $23.28
- 52W Low
- $1.36
- 50D MA
- $15.75
- 200D MA
- $17.08
- Beta
- 0.50
- RSI (14)
- 60
- Avg Volume
- 18.00K
No earnings-call transcripts are available for IKNA yet.
- Free Float
- 14.6%
- Shares Outstanding
- 41.89M
- Float Shares
- 6.11M
of shares held by institutions
46 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Chi Advisors LLC | 2.18M | ▲ 58.89K |
| Blackrock Inc. | 354.84K | ▼ 1.47M |
| Oup Management Co., LLC | 26.83K | ▲ 26.83K |
| Baystate Wealth Management LLC | 3.00K | 0 |
Held by 10 ETFs
Biggest fund positions in IKNA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 4, 23 | ORBIMED ADVISORS LLC | other | 153,121 |
| Aug 4, 23 | ORBIMED ADVISORS LLC | other | 353,192 |
| Aug 4, 23 | Bonita David P | other | 153,121 |
| Aug 4, 23 | Bonita David P | other | 353,192 |
| Dec 14, 22 | Hughes Owen | other | 0 |
| Apr 15, 21 | Koehler Maria | other | 26,838 |
| Mar 30, 21 | Bonita David P | other | 5,429,023 |
| Mar 30, 21 | Bonita David P | buy | 375,000 |
| Mar 30, 21 | Bonita David P | other | 1,470,872 |
| Mar 30, 21 | Bonita David P | other | 157,288 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IKNA coverage
Recent articles, reports, and earnings notes.
No research on IKNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IKNA report →Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
globenewswire.com · Jul 25
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
globenewswire.com · Jul 23
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
globenewswire.com · Jul 15
Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals
globenewswire.com · Jul 11
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade
zacks.com · Dec 30
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
globenewswire.com · Dec 23
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
globenewswire.com · Dec 23
Ikena Oncology Reports Third Quarter 2024 Financial Results
globenewswire.com · Nov 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.